Medscape is available in 5 Language Editions – Choose your Edition here.


Burkitt Lymphoma and Burkitt-like Lymphoma Treatment & Management

  • Author: Ali H Kanbar, MD; Chief Editor: Emmanuel C Besa, MD  more...
Updated: Apr 08, 2016

Approach Considerations

Burkitt lymphoma (BL) is a very fast growing tumor. Patients should be admitted to the hospital for rapid workup and diagnostic measures. Chemotherapy is the mainstay of treatment for this disease; consultation with a hematologist and oncologist should be obtained as soon as possible. No role exists for surgery or radiation therapy in the treatment of Burkitt lymphomaL).

It is critical to closely monitor serum chemistries in patients with Burkitt lymphoma (BL), especially during chemotherapy because of the high risk of tumor lysis syndrome and uric acid nephropathy. Prophylactic allopurinol and aggressive hydration with urine alkalinization should be administered.

Intravenous antibiotics should be administered for neutropenic fevers. Growth factors (granulocyte-macrophage colony-stimulating factor [GM-CSF] or granulocyte colony-stimulating factor [G-CSF]) are administered to help decrease the duration of neutropenia.

Transfusions (red blood cells or platelets) are administered as clinically indicated for anemia and thrombocytopenia. All blood products should be leukodepleted and irradiated.

Measures to prevent tumor lysis syndrome

Maintain adequate hydration through intravenous (IV) fluids, ideally starting 24 hours before administering chemotherapy. Note, however, that many patients require chemotherapy emergently and, in these patients, therapy should not be delayed.

Maintain high urine outflow (200-250 mL/m2/h), and monitor renal function closely.

Most patients with Burkitt lymphoma are considered at high risk for tumor lysis and meet the criteria for upfront treatment with rasburicase, which should be administered at a dose of 0.20 mg/kg IV daily for 5 days. Note that patients receiving rasburicase should not have alkalinization of the urine and that this agent is contraindicated in patients with glucose-6-phospate deficiency (G6PD). Lower-risk patients and those who cannot tolerate rasburicase can receive allopurinol, 300 mg twice daily

Close monitoring of the complete blood cell (CBC) count, coagulation studies, and at least twice-daily measurement of serum uric acid, potassium, calcium, phosphorus, magnesium, and creatinine levels is necessary for the first several days of treatment. Consider placing the patient on a cardiac monitor for the first few days. Liver function results should also be monitored.

Treatment should be performed at a facility where renal dialysis is available should it be necessary, particularly for patients with extensive disease.


In addition to obtaining a consultation with a hematologist and hematopathologist should as soon as possible, various subspecialty consultations may be required as indicated by clinical situations, such as renal consultation for patients presenting with, or developing, renal failure (uric acid nephropathy) that may require dialysis and surgical consultation for excisional lymph node or tissue biopsy and central line/port placement


Patients should be treated in a facility where the physicians are familiar with the use of intensive chemotherapy regimens. The facility should have access to hematopathology and physicians experienced in the prevention and treatment of renal failure from tumor lysis. Adequate blood product support should be available.

Diet and activity restrictions

Most centers advise a neutropenic diet, and patients with significant renal dysfunction should receive a renal diet.

Most patients with Burkitt lymphoma are acutely ill and in the hospital at diagnosis. Their activities will be extremely limited at this time. As the patient responds to therapy, they can increase their activity appropriately. Patients with significant anemia will be limited by fatigue. These patients should appropriately restrict activities that require intense concentration. Patients with significant thrombocytopenia should not perform strenuous activities.


Chemotherapy Overview

Intensive systemic chemotherapy is the treatment of choice for this aggressive disease in all its stages.[31] All clinical variants of Burkitt lymphoma are treated generally the same. The overall survival rate associated with Burkitt lymphoma depends upon the stage of the disease at initial diagnosis. Patients with localized disease respond well to chemotherapy and have an excellent survival rate. Patients with disseminated disease respond less well to chemotherapy and have a less favorable survival rate. Increasing age has also been associated with inferior outcome in most clinical trials.[7, 53] (See Staging and Prognosis.)

For patients who refuse, or are not candidates for clinical trials, short-duration, intensive, alkylator-based, multiagent chemotherapy regimens with adequate central nervous system (CNS) prophylaxis are necessary. Administration of less intensive chemotherapy regimens used in other non-Hodgkin lymphomas (NHL) (eg, CHOP [cyclophosphamide, hydroxydaunorubicin hydrochloride (doxorubicin hydrochloride), vincristine and prednisone]) usually results in frequent relapses and inferior survival. Of particular importance is the rapid administration of successive cycles of intensive multidrug therapy to prevent tumor regrowth. Dose reduction should also be avoided if possible.[54]

Most adult Burkitt lymphoma regimens were initially adopted from the pediatric study protocols that used several known active agents, including cyclophosphamide, vincristine, methotrexate, doxorubicin, and cytarabine. The French (LMB 81, 84, 86, and 89) and the German (B-NHL 83, B-NHL 86) protocols as well as the CODOX-M/IVAC regimen (cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate / ifosfamide, etoposide, high-dose cytarabine) were modified and used in adult patients with acceptable outcomes (2-y overall survival: 40-74%). Other protocols (hyper-CVAD [modified fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone], Cancer and Leukemia Group B [CALGB] 9251, etc) were evaluated primarily in adults.

A study by Todeschini et al found that intensive pediatric-based chemotherapy regimen increased remission and survival rates in both children and adults with Burtkitt lymphoma.[55]

Even though a standard regimen is not available yet, in general, three treatment approaches are available:

  • Intensive, short-duration regimens like CODOX-M/IVAC (Magrath regimen) and the CALGB 9251 protocol
  • Long-duration chemotherapy similar to acute lymphoblastic leukemia (ALL) treatment, like hyper-CVAD and the CALGB 8811 protocol
  • Combination regimens followed by autologous stem cell transplantation (SCT)
  • Most current regimens have added rituximab to previously established chemotherapy regimens

Despite the fact that no direct comparison has been done among these different approaches, the short-duration, more intense regimens are usually preferred in most US institutions, because they are faster to administer (ALL-type treatment may take up to 2 y and usually involves a maintenance arm) and less complicated than ALL-type treatment or SCT. The regimen most frequently used is CODOX-M/IVAC.


Each of the above mentioned regimens carries a 60-70% chance of prolonged progression-free and overall survival, but that is unfortunately associated with a significant toxicity profile. No toxic deaths were reported in the initial study by Magrath (CODOX-M/IVAC), but the rate of grade 3/4 neutropenia was 100%; thrombocytopenia, 96%; mucositis, 61%; and sepsis, 22%. Similar toxicities were seen on the CALGB 9251 protocol.

CNS prophylaxis

CNS prophylaxis using intrathecal methotrexate with or without cytarabine and hydrocortisone is included in most regimens. Without CNS prophylaxis, 30-50% of patients will develop CNS relapse. With the above mentioned regimens, the rate of CNS relapse drops to about 6-11%.[56] Use of prophylactic cranial irradiation causes increased neurologic toxicity; in the 2004 update of the CALGB 9251, the protocol was amended to restrict its use to patients with bone marrow involvement only. This did not significantly affect the rate of CNS relapse.


CODOX-M/IVAC Regimen (Magrath Regimen)

The CODOX-M/IVAC (cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate / ifosfamide, etoposide, high-dose cytarabine) regimen consists of 4 cycles, each cycle lasting until blood counts recover (absolute neutrophil count [ANC] > 1000/μL; platelets > 100,000/μL). Cycles 1 and 3 involve CODOX-M, and cycles 2 and 4 involve IVAC. Three cycles of CODOX-M are usually enough for low-risk patients, whereas high-risk patients receive 4 total cycles (2 cycles of CODOX-M, alternating with 2 cycles of IVAC).[27]


The CODOX-M regimen is as follows:

  • Cyclophosphamide 800mg/m 2 IV on day 1, followed by 200 mg/m 2 IV on days 2-5
  • Doxorubicin 40 mg/m 2 IV on day 1
  • Vincristine 1.5 mg/m 2 IV (no capping of dose) on days 1 and 8 (cycle 1), as well as on days 1, 8, and 15 (cycle 3)
  • Methotrexate 1200 mg/m 2 IV over 1 hour on day 10; then 240 mg/m 2/h for the next 23 hours; leucovorin rescue begins 36 hours from the start of the methotrexate infusion
  • Intrathecal cytarabine 70 mg (patient older than age 3 y) on days 1 and 3
  • Intrathecal methotrexate 12 mg (patient older than age 3 y) on day 15


The IVAC regimen is as follows:

  • Ifosfamide 1500 mg/m 2 IV on days 1-5, with mesna protection
  • Etoposide 60 mg/m 2 IV on days 1-5
  • Cytarabine 2 g/m 2 IV every 12 hours on days 1-2
  • Intrathecal methotrexate 12 mg (patient older than age 3 y) on day 5

Administration of colony-stimulating factors is usually started 24 hours after completion of chemotherapy and continues until the ANC >1000/μL. See the Absolute Neutrophil Count calculator.

CNS involvement

If central nervous system (CNS) involvement is documented, patients are treated with a more intense intrathecal regimen during cycles 1 and 2. Cytarabine 70 mg (15 mg if administered into an Ommaya reservoir) is given on days 1, 3, and 5 of cycle 1 as well as on days 7 and 9 of cycle 2; in addition, intrathecal methotrexate 12.5 mg (2 mg if via Ommaya reservoir) on days 15 and 17 (cycle 1) and day 5 (cycle 2). For cycles 3 and 4, the usual prophylactic intrathecal doses of cytosine arabinoside (Ara-C) and methotrexate are given.

The MRC/NCRI LY1O trial investigated a modified dose of methotrexate (3 g/m2) and showed an overall survival of 67%, with decreased toxicity compared with the previous LY06 trial with full-dose methotrexate (6.7 g/m2).[57]


CALGB 9251 Regimen

The Cancer and Leukemia Group B (CALGB) launched a multidrug regimen pilot study (9251) of high-intensity, brief-duration chemotherapy. A brief schema of this protocol is discussed in this section.[58, 59]

Note: Courses II, IV, and VI and courses III, V, and VII are similar and described together. Courses II-VI are administered at 21-day intervals

Course I consists of cyclophosphamide 200 mg/m2/d IV on days 1-5; prednisone 60 mg/m2/d by mouth (PO) on days 1-7.

Courses II, IV, and VI comprise the following:

  • Ifosfamide 800 mg/m 2 IV over 1 hour on days 1-5
  • Mesna 200 mg/m 2 IV on days 1-5 (at 0, 4, and 8 h after ifosfamide)
  • Methotrexate 150 mg/m 2 IV over 30 minutes on day 1, followed by 1.35 g/m 2 IV over the next 23.5 hours (total dose: 1.5 g/m 2)
  • Leucovorin 50 mg/m 2 IV starting 36 hours after methotrexate, then 15 mg/m 2 every 6 hours until serum methotrexate levels are <5 × 10 -8 M (0.05 μM)
  • Vincristine 2 mg IV bolus on day 1
  • Cytarabine (Ara-C) 150 mg/m 2/day by continuous infusion over 48 hours (days 4-5)
  • Etoposide 80 mg/m 2 IV over 1 hour on days 4-5
  • Dexamethasone 10 mg/m 2 PO per day on days 1-5

Courses III, V, and VII comprise the following:

  • Cyclophosphamide 200 mg/m 2 IV daily on days 1-5
  • Methotrexate 150 mg/m 2 IV over 30 minutes on day 1, followed by 1.35 g/m 2 IV over the next 23.5 hours (total dose: 1.5 g/m 2)
  • Leucovorin 50 mg/m 2 IV starting 36 hours after methotrexate, then 15 mg/m 2 every 6 hours until serum methotrexate levels are < 5 × 10 -8 M (0.05 μM)
  • Vincristine 2 mg IV bolus on day 1
  • Adriamycin (doxorubicin) 25 mg/m 2 IV bolus on days 4-5
  • Dexamethasone 10 mg/m 2 PO daily on days 1-5

Intrathecal chemotherapy consists of methotrexate 15 mg plus cytarabine 40 mg plus hydrocortisone 50 mg, all administered on day 1 of each course (II-VII).

Cranial radiation (amended in the 2004 update of the CALGB 9251: Only for those patients with previous bone marrow involvement): 2400 cGy in 12 fractions, administered at least 21 days after course VII.


Hyper-CVAD Regimen

The hyper-CVAD (modified fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone) regimen consists of alternating A (1, 3, 5, and 7) and B (2, 4, 6, and 8) cycles. The second and subsequent cycles are administered when the patient's white blood cell (WBC) count is more than 3,000/mm3, and the platelet count is higher than 60,000/mm3 (between 14 and 21 d).

Cycle A comprises the following:

  • Cyclophosphamide 300 mg/m 2 intravenously (IV) over 2 hours every 12 hours for 6 doses, on days 1-3
  • Mesna 600 mg/m 2 by continuous IV infusion over 24 hours, starting 1 hour before cyclophosphamide and continuing for 12 hours after the last dose of cyclophosphamide
  • Vincristine 2 mg/dose IV push over 2-3 minutes for 2 doses on days 4 and 11
  • Doxorubicin 50 mg/m 2 IV over 2 hours on day 4
  • Dexamethasone 40 mg/day orally (PO) or IV for 8 doses on days 1-4 and on days 11-14
  • Filgrastim 10 mcg/kg/day subcutaneously (SC) starting 24 hours after the last dose of chemotherapy and continuing until the WBC count is >3000/mm 3

Cycle B comprises the following:

  • Methotrexate 1000 mg/m 2 by continuous IV infusion over 24 hours on day 1
  • Cytarabine 3,000 mg/m 2 IV over 2 hours every 12 hours for 4 doses, on days 2-3
  • Calcium leucovorin 50 mg IV over 20 minutes administered 12 hours after methotrexate infusion is completed, followed 6 hours later by leucovorin 15 mg IV every 6 hours for 8 total doses or until blood methotrexate concentration is < 0.1 µmol/L
  • Filgrastim 10 mcg/kg/day SC starting 24 hours after the last dose of chemotherapy and continuing until the WBC count is > 3000/mm 3

Calcium leucovorin doses should be escalated to 50 mg IV every 6 hours if serum methotrexate concentrations are the following:

  • Greater than 20 µmol/L at the end of the methotrexate infusion (hour 24)
  • Greater than 1 µmol/L at 24 hours after the end of the methotrexate infusion (hour 48)
  • Greater than 0.1 µmol/L at 48 hours after the end of the methotrexate infusion (hour 72)

CNS prophylaxis

See the list below:

  • Methotrexate intrathecally on day 2 of each cycle, 12 mg/dose via lumbar puncture or 6 mg/dose via Ommaya reservoir
  • Cytarabine 100 mg/dose intrathecally via lumbar puncture or Ommaya reservoir administered on day 7 for 8 cycles


Rituximab is a recombinant antibody that targets CD20 on the surface of B lymphocytes. Many studies have incorporated rituximab into the treatment of Burkitt lymphoma. When Oriol et al investigated the addition of rituximab to an intense chemotherapy regimen containing methotrexate, cyclophosphamide, vincristine, ifosfamide, and teniposide (NHL2002 protocol from GMALL [German Multicenter Study Group on Adult Acute Lymphoblastic Leukemia] study) in treating 36 patients, 19 (53%) of whom were HIV positive, complete remission (CR) rates were 88% for HIV-negative patients and 84% for HIV-positive patients.[60]

HIV-positive patients had a higher rate of mucositis and infectious diarrhea, but there was no statistically significant difference in 2-year overall survival between the 2 groups of patients.[60] The HIV-positive patients were all treated concurrently with highly active anti-retroviral therapy (HAART).[60] An improvement in the 3-year estimated survival, disease-free survival (DFS), and event-free survival (EFS) rates, particularly for the elderly, were seen in patients with Burkitt lymphoma receiving rituximab compared with historical controls who did not receive rituximab.

Rituximab has also been evaluated prospectively in small studies, in combination with hyper-CVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone)[26] and dose-adjusted EPOCH (etoposide, vincristine, doxorubicin, cyclophosphamide, and prednisone).[61] Complete remissions were seen in 86-100% of patients. Rituximab is therefore recommended in the treatment of BL patients, probably to be started with cycle 2, in order to decrease the risk of tumor lysis with the first cycle. CALGB is currently recruiting for a trial looking specifically at the role of rituximab (CALGB 10002).


Evaluation of Treatment Response

After completion of chemotherapy, the response to treatment should be investigated. This should include patient history, physical examination, laboratory studies (complete blood cell (CBC) count, renal/liver profiles, and lactate dehydrogenase [LDH] levels) ,and posttherapy imaging, preferably computed tomography (CT) scans (see Workup).

A complete remission is achieved if the patient has no evidence of disease or disease-related symptoms and if all the masses or lymph nodes that were previously present have resolved on the posttreatment CT scan. If the bone marrow was involved before treatment, a repeat bone marrow biopsy should be normal.


Relapsed/Refractory Burkitt Lymphoma

The majority of relapses occur during the first year of treatment for Burkitt lymphoma. Failure to achieve complete remission is a very poor prognostic sign. Those who remain free from disease at 10-12 months are considered cured, although reports of delayed relapses have been described in the African population and in patients with concurrent human immunodeficiency virus (HIV) infection.

The best management approach to these patients is not well defined. Most patients in this group respond poorly to salvage therapy, although some patients are reported to have long-term survival.

The salvage regimen typically incorporates chemotherapeutic agents to which the patient has had no previous exposure. The DHAP (dexamethasone at 40 mg PO for 4 d, high-dose cytarabine [Ara-C] at 2000 mg/m2 IV q12h for 2 doses, and cisplatin at 100 mg/m2 IV for 1 dose) regimen is often used as salvage therapy. Among these patients, those whose disease demonstrates some chemosensitivity are then referred for high-dose chemotherapy and autologous stem cell transplantation (SCT)/bone marrow transplantation (or allogeneic SCT in clinical trials). Patients with chemoresistant disease are usually referred for best supportive care (see the Sweetenham et al reference[62] ).


Stem Cell Transplantation

The use of high-dose chemotherapy plus stem cell transplantation (SCT) has decreased because of the high rate of remission achieved with current treatment regimens.

High-dose chemotherapy plus autologous SCT may be considered for patients whose condition has not responded to (primary refractory) or who have relapsed after first-line conventional chemotherapy. The outcome for adult patients treated with a short, intensive regimen is less favorable than the outcome in children. Up to 40% of the patients treated on the LMB81 and LMB84 regimens experienced relapse; this rate is lower in patients treated with CODOX-M/IVAC (cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate / ifosfamide, etoposide, high-dose cytarabine).[27] Current indications for treatment of these patients with high-dose chemotherapy plus autologous SCT remain similar to those of the pediatric group.

Primary refractory disease

Patients with primary refractory disease do not respond well to high-dose chemotherapy plus autologous SCT. The duration of responses in these patients is often short, with eventual relapse in most reported series. Alternative approaches, including allogeneic SCT/bone marrow transplantation or salvage regimens in the setting of a clinical trial, should be considered in these cases.[7, 63]

Partial remission

Patients in first partial remission should be considered for high-dose chemotherapy plus autologous SCT. The outcome of treatment in these patients with conventional chemotherapy regimens is usually poor. In a report by Philip and Biron, the results of bone marrow transplantation in patients with Burkitt lymphoma (BL) in partial remission was a 70% survival rate at 2 years.[64]

Subsequent randomized studies in aggressive non-Hodgkin lymphoma (NHL) have failed to clearly show an advantage for high-dose chemotherapy plus autologous SCT. Currently, patients with Burkitt lymphoma (BL) whose disease demonstrates chemosensitivity and who achieve a good partial remission after front-line therapy should be considered for high-dose chemotherapy plus autologous SCT.[25]

Clinical remission

Patients in first clinical remission with poor prognostic features have been considered for consolidation therapy with high-dose chemotherapy plus autologous SCT. Published data to date do not support the use of this approach outside of a clinical trial.[65]


A French group has reported improved survival rates in patients with relapsed aggressive NHL who were treated with high-dose chemotherapy plus autologous SCT.[66] The only significant prognostic factor noted was sensitivity to reinduction chemotherapy at the time of relapse. A 3-year survival rate of 36% in sensitive relapse (SR) versus 14% in resistant relapse (RR) was reported.[66] Subsequent studies have reported similar outcomes.

Patients with relapsed Burkitt lymphoma (BL) with chemosensitive disease should be considered for high-dose chemotherapy plus autologous SCT; alternative therapies should be considered for those with RR (see the Sweetenham et al reference[62] ).

SCT and graft vs leukemia effect

The role of allogeneic SCT and graft versus leukemia effect in Burkitt lymphom or Burkitt-like lymphoma remains investigational.[67, 68] Many transplant centers consider this option for patients at high risk and for those with refractory disease. There have also been case reports that suggested a possible role for nonablative and cord blood transplantation in relapsed heavily treated patients.[69]


Surgical Intervention

In current clinical practice, effective and durable responses are observed with combination chemotherapy, obviating the role of surgical debulking. Historically, most patients with Burkitt lymphoma who presented with large masses, particularly abdominal disease, underwent an exploratory laparotomy, at which time an effort was made to debulk as well.

With newer, sophisticated interventional radiology approaches, an adequate diagnosis can be reached in almost all patients without major surgical intervention. Palliative surgery is considered only for patients with obstruction who cannot begin chemotherapy immediately.

Tracheotomy is indicated if the patient's airway is compromised from the physical pressure of a large tumor mass.

Exploratory laparotomy may be performed for bowel obstruction (often before the diagnosis is made). Patients with uncontrolled gastrointestinal bleeding may also need exploratory laparotomy or endoscopic procedures for hemostasis.

Pericardiocentesis is indicated for patients presenting with cardiac tamponade.

Paracentesis is indicated if large ascites is one of the presenting complaints.

An excisional lymph node biopsy is usually necessary to reach an accurate diagnosis.

A semi-permanent intravenous catheter such as a peripherally inserted central catheter (PICC) line or medicine port should be arranged with interventional radiology or surgery to aid administration of chemotherapy, medications, and blood products and for fluid management.


Long-Term Monitoring

When patients with Burkitt lymphoma receive treatment in the clinic, close monitoring of their white blood cell (WBC) count, hemoglobin, platelet count, serum chemistry levels, and liver functions is needed.

After chemotherapy is completed, patients should be monitored at least every 2 months during the first year, then every 3 months the following year, and every 6 months thereafter.

During follow-up visits, a complete physical examination should be performed, and CBC count and serum electrolyte levels should be obtained. Lactate dehydrogenase (LDH) and beta2 microglobulin studies may be helpful in detecting early relapse.

Repeat staging with computed tomography (CT) scanning is performed during and after completion of treatment to ascertain disease response and document achievement of complete remission.


Special Considerations

Burkitt lymphoma and Burkitt-like lymphoma have an aggressive clinical course; therefore, management should be directed toward an expeditious diagnosis, followed by prompt institution of definitive therapy. Initial treatment should be started in an inpatient setting.

Patients with Burkitt lymphoma presenting with B symptoms should have a thorough examination, and a biopsy should be obtained immediately for any suspicious mass. Failure to diagnose this high-grade lymphoma can lead to long-term sequelae and, possibly, death.

Renal failure as a result of tumor lysis syndrome from therapy is a potential risk in all patients, especially those with a high tumor burden. Aggressive management of this potentially life-threatening complication should be clearly addressed. Early hemodialysis should be considered in these patients to prevent long-term renal dysfunction.

Contributor Information and Disclosures

Ali H Kanbar, MD Medical Oncologist/Hematologist, Dayton Cancer Center

Ali H Kanbar, MD is a member of the following medical societies: American College of Physicians, American Society of Hematology, American Society of Clinical Oncology

Disclosure: Nothing to disclose.


Ronald A Sacher, MB, BCh, FRCPC, DTM&H Professor, Internal Medicine and Pathology, Director, Hoxworth Blood Center, University of Cincinnati Academic Health Center

Ronald A Sacher, MB, BCh, FRCPC, DTM&H is a member of the following medical societies: American Association for the Advancement of Science, American Association of Blood Banks, American Society for Clinical Pathology, American Society of Hematology, College of American Pathologists, International Society on Thrombosis and Haemostasis, Royal College of Physicians and Surgeons of Canada, American Clinical and Climatological Association, International Society of Blood Transfusion

Disclosure: Serve(d) as a speaker or a member of a speakers bureau for: GSK Pharmaceuticals,Alexion,Johnson & Johnson Talecris,,Grifols<br/>Received honoraria from all the above companies for speaking and teaching.

Chief Editor

Emmanuel C Besa, MD Professor Emeritus, Department of Medicine, Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Kimmel Cancer Center, Jefferson Medical College of Thomas Jefferson University

Emmanuel C Besa, MD is a member of the following medical societies: American Association for Cancer Education, American Society of Clinical Oncology, American College of Clinical Pharmacology, American Federation for Medical Research, American Society of Hematology, New York Academy of Sciences

Disclosure: Nothing to disclose.


Patturajah Anbumani, MD, MBBS, MS, MCh Associate Medical Director, Best Medical Care; Former Associate Medical Director, Jeanes Hospital, Temple University Health System; Former Adjunct Clinical Assistant Professor, New York College of Osteopathic Medicine; Former Clinical Assistant Professor, Department of Medicine, State University of New York-Downstate

Patturajah Anbumani, MD, MBBS, MS, MCh is a member of the following medical societies: American College of Physicians, American Medical Association, and American Medical Women’s Association

Disclosure: Nothing to disclose.

Samer A Bleibel, MD Staff Physician, Department of Internal Medicine, Wayne State University School of Medicine, St John's Hospital and Medical Centers

Samer A Bleibel, MD is a member of the following medical societies: American College of Physicians

Disclosure: Nothing to disclose.

Asher A Chanan-Khan, MD Assistant Professor, Department of Medicine, Division of Lymphoma and Bone Marrow Transplantation, Roswell Park Cancer Institute, State University of New York at Buffalo

Asher A Chanan-Khan, MD is a member of the following medical societies: American College of Physicians, American Medical Association, and American Society of Hematology

Disclosure: Nothing to disclose.

Hanxian Huang, MD, PhD Staff Physician, Department of Internal Medicine, Leesburg Regional Medical Center, The Villages Regional Hospital

Hanxian Huang, MD, PhD is a member of the following medical societies: American College of Physicians-American Society of Internal Medicine

Disclosure: Nothing to disclose.

Anand B Karnad, MBBS Program Director, Fellowship Programs in Hematology-Oncology, Professor of Medicine, Division of Medical Oncology, Department of Medicine, University of Texas Health Sciences Center, San Antonio

Anand B Karnad, MBBS is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American Osler Society, American Society of Hematology, Assocation of Subspecialty Professors, and Massachusetts Medical Society

Disclosure: Nothing to disclose.

Olga Kozyreva, MD Attending Physician, Division of Hematology-Oncology, St Elizabeth's Medical Center; Assistant Professor, Tufts University School of Medicine

Disclosure: Nothing to disclose.

Sarah K May, MD Consulting Staff, Department of Hematology-Oncology, Caritas Carney Hospital, Commonwealth Hematology-Oncology PC

Disclosure: Nothing to disclose.

from Memorial Sloan-Kettering - Philip Schulman, MD Chief, Medical Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center; Clinical Professor, Department of Medicine, New York University School of Medicine

Philip Schulman, MD is a member of the following medical societies: American Association for Cancer Research, American College of Physicians, American Society of Hematology, and Medical Society of the State of New York

Disclosure: Nothing to disclose.

Karen Seiter, MD Professor, Department of Internal Medicine, Division of Oncology/Hematology, New York Medical College

Karen Seiter, MD is a member of the following medical societies: American Association for Cancer Research, American College of Physicians, and American Society of Hematology

Disclosure: Novartis Honoraria Speaking and teaching; Schering Honoraria Speaking and teaching; Cephalon Honoraria Speaking and teaching; Celgene Honoraria Speaking and teaching

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Yubao Wang, MD, PhD Fellow, Division of Hematology/Medical Oncology, University of Texas Health Science Center, San Antonio

Yubao Wang, MD, PhD is a member of the following medical societies: American College of Physicians, American Society of Clinical Oncology, and American Society of Hematology

Disclosure: Nothing to disclose.

  1. Molyneux EM, Rochford R, Griffin B, Newton R, Jackson G, Menon G, et al. Burkitt's lymphoma. Lancet. 2012 Mar 31. 379 (9822):1234-44. [Medline].

  2. Boerma EG, van Imhoff GW, Appel IM, Veeger NJ, Kluin PM, Kluin-Nelemans JC. Gender and age-related differences in Burkitt lymphoma--epidemiological and clinical data from The Netherlands. Eur J Cancer. 2004 Dec. 40(18):2781-7. [Medline].

  3. Leoncini L, Raphael M, Stein H, Harris NL, Jaffe ES, Kluin PM. Burkitt Lymphoma. Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008. 262-4.

  4. Gong JZ, Stenzel TT, Bennett ER, et al. Burkitt lymphoma arising in organ transplant recipients: a clinicopathologic study of five cases. Am J Surg Pathol. 2003 Jun. 27(6):818-27. [Medline].

  5. Husain M, Grunebaum E, Naqvi A, et al. Burkitt's lymphoma in a patient with adenosine deaminase deficiency-severe combined immunodeficiency treated with polyethylene glycol-adenosine deaminase. J Pediatr. 2007 Jul. 151(1):93-5. [Medline].

  6. Ferry JA. Burkitt's lymphoma: clinicopathologic features and differential diagnosis. Oncologist. 2006 Apr. 11(4):375-83. [Medline].

  7. Blum KA, Lozanski G, Byrd JC. Adult Burkitt leukemia and lymphoma. Blood. 2004 Nov 15. 104(10):3009-20. [Medline].

  8. Burkitt DP. Classics in oncology. A sarcoma involving the jaws in African children. CA Cancer J Clin. 1972 Nov-Dec. 22(6):345-55. [Medline].

  9. Burkitt D, O'Conor GT. Malignant lymphoma in African children. I. A clinical syndrome. Cancer. 1961 Mar-Apr. 14:258-69. [Medline].

  10. Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet. 1964 Mar 28. 1(7335):702-3. [Medline].

  11. Magrath I. The pathogenesis of Burkitt's lymphoma. Adv Cancer Res. 1990. 55:133-270. [Medline].

  12. Magrath IT. African Burkitt's lymphoma. History, biology, clinical features, and treatment. Am J Pediatr Hematol Oncol. 1991 Summer. 13(2):222-46. [Medline].

  13. De Falco G, Antonicelli G, Onnis A, Lazzi S, Bellan C, Leoncini L. Role of EBV in microRNA dysregulation in Burkitt lymphoma. Semin Cancer Biol. 2009 Dec. 19(6):401-6. [Medline].

  14. Thorley-Lawson DA, Allday MJ. The curious case of the tumour virus: 50 years of Burkitt's lymphoma. Nat Rev Microbiol. 2008 Dec. 6(12):913-24. [Medline].

  15. Preudhomme C, Dervite I, Wattel E, et al. Clinical significance of p53 mutations in newly diagnosed Burkitt's lymphoma and acute lymphoblastic leukemia: a report of 48 cases. J Clin Oncol. 1995 Apr. 13(4):812-20. [Medline].

  16. Gaidano G, Ballerini P, Gong JZ, et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 1991 Jun 15. 88(12):5413-7. [Medline]. [Full Text].

  17. Dang CV, Resar LM, Emison E, et al. Function of the c-Myc oncogenic transcription factor. Exp Cell Res. 1999 Nov 25. 253(1):63-77. [Medline].

  18. Dang CV, O'Donnell KA, Juopperi T. The great MYC escape in tumorigenesis. Cancer Cell. 2005 Sep. 8(3):177-8. [Medline].

  19. Coller HA, Grandori C, Tamayo P, et al. Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci U S A. 2000 Mar 28. 97(7):3260-5. [Medline]. [Full Text].

  20. Molina-Privado I, Rodriguez-Martinez M, Rebollo P, et al. E2F1 expression is deregulated and plays an oncogenic role in sporadic Burkitt's lymphoma. Cancer Res. 2009 May 1. 69(9):4052-8. [Medline]. [Full Text].

  21. Davi F, Delecluse HJ, Guiet P, et al. Burkitt-like lymphomas in AIDS patients: characterization within a series of 103 human immunodeficiency virus-associated non-Hodgkin's lymphomas. Burkitt's Lymphoma Study Group. J Clin Oncol. 1998 Dec. 16(12):3788-95. [Medline].

  22. Cardy HA, Sharp L, Little J. Burkitt's lymphoma: a review of the epidemiology. Kuwait Med J. 2001. 33:293-306.

  23. Makata AM, Toriyama K, Kamidigo NO, Eto H, Itakura H. The pattern of pediatric solid malignant tumors in western Kenya, east Africa, 1979-1994: an analysis based on histopathologic study. Am J Trop Med Hyg. 1996 Apr. 54(4):343-7. [Medline].

  24. Havelange V, Pepermans X, Ameye G, Théate I, Callet-Bauchu E, Barin C, et al. Genetic differences between paediatric and adult Burkitt lymphomas. Br J Haematol. 2016 Apr. 173 (1):137-44. [Medline].

  25. Ladenstein R, Pearce R, Hartmann O, Patte C, Goldstone T, Philip T. High-dose chemotherapy with autologous bone marrow rescue in children with poor-risk Burkitt's lymphoma: a report from the European Lymphoma Bone Marrow Transplantation Registry. Blood. 1997 Oct 15. 90(8):2921-30. [Medline].

  26. Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006 Apr 1. 106(7):1569-80. [Medline].

  27. Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol. 1996 Mar. 14(3):925-34. [Medline].

  28. Kantarjian HM, Walters RS, Keating MJ, et al. Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia. J Clin Oncol. 1990 Jun. 8(6):994-1004. [Medline].

  29. Ostronoff M, Soussain C, Zambon E, et al. Burkitt's lymphoma in adults: a retrospective study of 46 cases. Nouv Rev Fr Hematol. 1992. 34(5):389-97. [Medline].

  30. Hoelzer D, Ludwig WD, Thiel E, et al. Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood. 1996 Jan 15. 87(2):495-508. [Medline].

  31. McMaster ML, Greer JP, Greco FA, Johnson DH, Wolff SN, Hainsworth JD. Effective treatment of small-noncleaved-cell lymphoma with high-intensity, brief-duration chemotherapy. J Clin Oncol. 1991 Jun. 9(6):941-6. [Medline].

  32. Soussain C, Patte C, Ostronoff M, et al. Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols. Blood. 1995 Feb 1. 85(3):664-74. [Medline].

  33. Tholouli E, Watt S, Lucas GS, et al. Stage IV adult sporadic Burkitt lymphoma/leukemia with complex bone marrow cytogenetics is associated with a very poor outcome. Blood. 2009 Jul 9. 114(2):485-6; author reply 486-7. [Medline].

  34. Thomas DA, Cortes J, O'Brien S, et al. Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol. 1999 Aug. 17(8):2461-70. [Medline].

  35. Nelson R. New scoring system evaluates prognosis in Burkitt lymphoma. Medscape Medical News. August 14, 2013. Available at Accessed: August 19, 2013.

  36. Castillo JJ, Winer ES, Olszewski AJ. Population-based prognostic factors for survival in patients with Burkitt lymphoma: An analysis from the Surveillance, Epidemiology, and End Results database. Cancer. 2013 Jul 30. [Medline].

  37. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol. 1998 Aug. 16(8):2780-95. [Medline].

  38. Derinkuyu BE, Boyunağa Ö, Öztunalı Ç, Tekkeşin F, Damar Ç, Alımlı AG, et al. Imaging features of Burkitt lymphoma in pediatric patients. Diagn Interv Radiol. 2016 Jan-Feb. 22 (1):95-100. [Medline]. [Full Text].

  39. Gloria Silva F, Paiva M, Tavares A, et al. [Paediatric Burkitt lymphoma presenting as acute pancreatitis] [Portugese]. Acta Med Port. 2008 Sep-Oct. 21(5):515-20. [Medline].

  40. Legault S, Couture C, Bourgault C, Bergeron S, Poirier P, Sénéchal M. Primary cardiac Burkitt-like lymphoma of the right atrium. Can J Cardiol. 2009 Mar. 25(3):163-5. [Medline]. [Full Text].

  41. Gutierrez-Garcia L, Medina Ramos N, Garcia Rodriguez R, Barber MA, Arias MD, Garcia JA. Bilateral ovarian Burkitt's lymphoma. Eur J Gynaecol Oncol. 2009. 30(2):231-3. [Medline].

  42. Okudaira T, Nagasaki A, Miyagi T, Taira T, Ohshima K, Takasu N. Intensive chemotherapy for a patient with primary cutaneous diffuse large B-cell lymphoma with Burkitt-like morphology. Intern Med. 2009. 48(6):475-8. [Medline].

  43. Braziel RM, Arber DA, Slovak ML, et al. The Burkitt-like lymphomas: a Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features. Blood. 2001 Jun 15. 97(12):3713-20. [Medline].

  44. Kluin PM, Harris NL, Stein H, Leoncini L. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008. 265-7.

  45. Dogan A, Bagdi E, Munson P, Isaacson PG. CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol. 2000 Jun. 24(6):846-52. [Medline].

  46. McClure RF, Remstein ED, Macon WR, Dewald GW, Habermann TM, Hoering A. Adult B-cell lymphomas with burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior. Am J Surg Pathol. 2005 Dec. 29(12):1652-60. [Medline].

  47. Dave SS, Fu K, Wright GW, Lam LT, et al, for the Lymphoma/Leukemia Molecular Profiling Project. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med. 2006 Jun 8. 354(23):2431-42. [Medline].

  48. Hummel M, Bentink S, Berger H, et al, for the Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006 Jun 8. 354(23):2419-30. [Medline].

  49. Burmeister T, Schwartz S, Horst HA, Rieder H, Gokbuget N, Hoelzer D, et al. Molecular heterogeneity of sporadic adult Burkitt-type leukemia/lymphoma as revealed by PCR and cytogenetics: correlation with morphology, immunology and clinical features. Leukemia. 2005 Aug. 19(8):1391-8. [Medline].

  50. Küppers R, Klein U, Hansmann ML, Rajewsky K. Cellular origin of human B-cell lymphomas. N Engl J Med. 1999 Nov 11. 341(20):1520-9. [Medline].

  51. Garcia CF, Weiss LM, Warnke RA. Small noncleaved cell lymphoma: an immunophenotypic study of 18 cases and comparison with large cell lymphoma. Hum Pathol. 1986 May. 17(5):454-61. [Medline].

  52. Magrath IT, Janus C, Edwards BK, et al. An effective therapy for both undifferentiated (including Burkitt's) lymphomas and lymphoblastic lymphomas in children and young adults. Blood. 1984 May. 63(5):1102-11. [Medline].

  53. Smeland S, Blystad AK, Kvaloy SO, et al. Treatment of Burkitt's/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens. Ann Oncol. 2004 Jul. 15(7):1072-8. [Medline].

  54. Bishop PC, Rao VK, Wilson WH. Burkitt's lymphoma: molecular pathogenesis and treatment. Cancer Invest. 2000. 18(6):574-83. [Medline].

  55. Todeschini G, Bonifacio M, Tecchio C, et al. Intensive short-term chemotherapy regimen induces high remission rate (over 90%) and event-free survival both in children and adult patients with advanced sporadic Burkitt lymphoma/leukemia. Am J Hematol. 2012 Jan. 87(1):22-5. [Medline].

  56. Hill QA, Owen RG. CNS prophylaxis in lymphoma: who to target and what therapy to use. Blood Rev. 2006 Nov. 20(6):319-32. [Medline].

  57. Mead GM, Barrans SL, Qian W, et al, for the UK National Cancer Research Institute Lymphoma Clinical Studies Group and the Australasian Leukaemia and Lymphoma Group. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood. 2008 Sep 15. 112(6):2248-60. [Medline]. [Full Text].

  58. Lee EJ, Petroni GR, Schiffer CA, et al. Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. J Clin Oncol. 2001 Oct 15. 19(20):4014-22. [Medline].

  59. Rizzieri DA, Johnson JL, Niedzwiecki D, et al. Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251. Cancer. 2004 Apr 1. 100(7):1438-48. [Medline].

  60. Oriol A, Ribera JM, Bergua J, et al. High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients. Cancer. 2008 Jul 1. 113(1):117-25. [Medline].

  61. Dunleavy K, Pittaluga S, Janik J, et al. Novel treatment of Burkitt lymphoma with dose-adjusted EPOCH-rituximab: Preliminary results showing excellent outcome (abstract). Blood. 2006. 108:774A.

  62. Sweetenham JW, Pearce R, Taghipour G, Blaise D, Gisselbrecht C, Goldstone AH. Adult Burkitt's and Burkitt-like non-Hodgkin's lymphoma--outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse... J Clin Oncol. 1996 Sep. 14(9):2465-72. [Medline].

  63. Song KW, Barnett MJ, Gascoyne RD, et al. Haematopoietic stem cell transplantation as primary therapy of sporadic adult Burkitt lymphoma. Br J Haematol. 2006 Jun. 133(6):634-7. [Medline].

  64. Philip T, Biron P. High-dose chemotherapy and autologous bone marrow transplantation in diffuse intermediate- and high-grade non-Hodgkin lymphoma. Crit Rev Oncol Hematol. 2002 Feb. 41(2):213-23. [Medline].

  65. Nademanee A, Molina A, O'Donnell MR, et al. Results of high-dose therapy and autologous bone marrow/stem cell transplantation during remission in poor-risk intermediate- and high-grade lymphoma: international index high and high-intermediate risk group. Blood. 1997 Nov 15. 90(10):3844-52. [Medline].

  66. Philip T, Armitage JO, Spitzer G, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med. Jun 11 1987. 316(24):1493-8. [Medline].

  67. Grigg AP, Seymour JF. Graft versus Burkitt's lymphoma effect after allogeneic marrow transplantation. Leuk Lymphoma. 2002 Apr. 43(4):889-92. [Medline].

  68. Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al, for the European Bone Marrow Transplantation (EBMT) Lymphoma Registry. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant. 2003 Apr. 31(8):667-78. [Medline].

  69. Weinthal JA, Goldman SC, Lenarsky C. Successful treatment of relapsed Burkitt's lymphoma using unrelated cord blood transplantation as consolidation therapy. Bone Marrow Transplant. 2000 Jun. 25(12):1311-3. [Medline].

  70. Dunleavy K, Pittaluga S, Shovlin M, Steinberg SM, Cole D, Grant C, et al. Low-intensity therapy in adults with Burkitt's lymphoma. N Engl J Med. 2013 Nov 14. 369(20):1915-25. [Medline].

  71. Osterweil N. Burkitt's Yields to Longer-Duration, Lower-Dose Chemo. Medscape Medical News. Available at Accessed: November 26, 2013.

Computed tomography scan in a patient with a large, left-sided axillary mass from which a biopsy was obtained. Biopsy findings were consistent with small noncleaved cell non-Hodgkin lymphoma.
Postchemotherapy computed tomography scan in a patient diagnosed with small noncleaved cell lymphoma (SNCCL) (same patient as in previous image). This image shows regression of a left axillary mass.
Coronal magnetic resonance imaging (MRI) section in a patient with large neck mass (same patient as in previous image). Biopsy findings showed Burkitt-like non-Hodgkin lymphoma (NHL). MRI was performed to assess for cord involvement.
Sagittal magnetic resonance imaging (MRI) section of the neck area showing a large mass invading the cervical spine with epidural encroachment (same patient as in the previous image). MRI was performed to rule out cord compression. The first image shows the gallium scan of this patient that correlates with the site of the tumor.
Right-sided pleural effusion in a patient with small noncleaved cell lymphoma (SNCCL) non-Hodgkin lymphoma.
Hematoxylin and eosin (H&E) stain. Sheets of monotonous-appearing lymphoid cells with one or more prominent nucleoli and an area of pale staining resulting from the presence of benign macrophages reveal a starry sky pattern.
The 2-dimensional flow cytometry demonstrates the highlighted cells to be CD5 negative and CD23 negative as well as lambda negative. Small noncleaved cell lymphoma (SNCCL) cells are typically CD19+, CD20+, CD22+, and CD10+.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.